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Abstract 
Background : 
The incidence of renal diseases among paediatric age group is not uncommon and nephrotic 
syndrome is considered as the most common clinical and histopathological diagnosis among all 
types of renal diseases in children. However, there is a limited data on the distribution of various 
histopathological spectrum of biopsy proven renal diseases in the paediatric population from 
developing  countries.  
Patients  and methods: 
A retrospective as well as  prospective  study was performed from January 1997 to December 
2006 at our center involving  1480 children  ( age 1 month to 18 years) who have undergone 
renal biopsy. The data was complete in  887 patients and this was analyzed. 
Aim and objectives : 
 
1. To study the distribution of  various  renal diseases in pediatric age group in our center 
2. To analyze patient characteristics, clinical and biochemical parameters among each group 
of biopsy proven renal diseases. 
3. To study the various modality of treatment and its out come  among these patients. 
 
Results: 
The study included  887 children for whom  biopsy reports were available. There were  554 
males and 333 females. The distribution of various diseases were as follows: Minimal change 
disease in 303 (34.16%), Mesangial proliferative GN in 146 (16.45%), Lupus nephritis in 
98(11.05%), Proliferative glomerulonephritis in 81(9.13%), IgA nephropathy  in 61 (6.87%), 
Focal segmental glomerulosclerosis  in 59(6.65%), Diffuse mesangial hypercellularity in 
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53(5.97%), Membranous glomerulonephropathy  in 24(2.70%), Crescentic glomerulonephritis in 
15(1.69%), Membrano proliferative glomerulonephritis  in 8(0.9 %),Hemolytic uremic syndrome 
in 5 (0.56 %),Vasculitis in 3(0.33 %), acute interstitial nephritis in 3 (0.33 %),acute tubular 
necrosis  in 2(0.22 %), granulomatous interstitial nephritis in 3(0.33%), end stage etiology of 
unknown etiology in 17(1.92 %) and  inadequate sample in 2 (0.22%) children. Mean age at 
onset of  MCD  was 8.48 ± 4.7, 1-18 yrs years. In our patients, haematuria was seen in 9 % 
patients with MCD, 12.8 % patients with FSGS and 28.6% patients with MPGN. Hypertension 
was seen in 7% patients with MCD, 21.1%patients with FSGS and 12.1 % patients with MPGN.  
Conclusion: 
In children under 8 years of age, minimal change disease was the most common entity, whereas 
Focal segmental glomerulosclerosis predominated in children with age at onset greater than 8 
years. The age at onset of nephrotic syndrome was significantly higher in the non-MCD group 
than the MCD group. The incidence of hypertension, microhematuria, gross hematuria and was 
significantly lower in the MCD group. MCD remains the most common histopathological  
subtype in Indian children with  idiopathic nephrotic syndrome and the incidence  of  
Membranoproliferative glomerulonephritis  has been  found to have declined. The incidence of 
lupus  nephritis has increased. This study provides descriptive epidemiological biopsy data and 
highlights some important trends in changing prevalence of renal disease. 
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INTRODUCTION: 
The diagnostic approach to the renal biopsy obtained from a child follows the same 
principles as it does for adult specimens, for example an assessment of adequacy and the 
presence of chronic changes, and a systematic evaluation of the glomerular, tubulointerstitial and 
vascular components, followed by the use of adjunctive investigations such as 
immunohistochemistry and electron microscopy. There can, however, be significant differences 
in the appropriate interpretation of the findings present as a consequence of both differences in 
the relative frequencies of specific pathological conditions and the effect of physiological age-
related changes. The spectrum of paediatric renal disease encompasses the majority of entities 
seen in adult practice, although with a much lower incidence for many of these, in addition to a 
number of conditions either unique to or much more frequent in childhood. For this reason, 
although general renal biopsy processing or handling in the laboratory is identical irrespective of 
patient age, it is especially important to routinely process part of the biopsy for ultra structural 
examination in specimens from children as conditions such as Alport nephropathy and thin 
glomerular basement membrane (TGBM) disease can only be diagnosed by appropriate electron 
microscopic examination1. 
For some conditions, such as lupus nephritis, the role of the biopsy in childhood is 
identical to that in adult practice, namely to allow risk stratification and direct patient 
management, but the distribution of the histological patterns may be different from the adult 
population. 
In other conditions, however, such as congenital nephrotic syndrome (CNS), biopsy is for 
primary diagnostic purposes, with the main differential diagnoses having no counterparts in adult 
practice. 
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REVIEW OF LITERATURE: 
The routine evaluation of a percutaneous renal biopsy involves examination of the tissue 
under light microscopy, immunofluorescence (immunoperoxidase in some laboratories)2 , and 
electron microscopy. Each component of the evaluation can provide important diagnostic 
information. The routine immunofluorescence examination of biopsy specimens should include 
(at a minimum) evaluation of IgG, IgM, IgA, C3, C1q, albumin, fibrin, and kappa and lambda 
immunoglobulin light chains. 
Justification for the routine application of electron microscopy comes largely from 
studies in the 1960s and 1970s, which showed that this technique provided substantive diagnostic 
information beyond that obtained from light microscopy in nearly 50 percent of cases. However, 
most of these studies were performed at a time when immunofluorescence microscopy was not 
widely available. 
To assess the present utility of electron microscopy, a study of 288 native renal biopsies 
performed over a six-month period in 1996 examined the diagnostic findings provided by light, 
immunofluorescence, and electron microscopy3. When viewed in combination with the results 
from light and immunofluorescence microscopy, electron microscopy provided: 
• Required diagnostic information in 50 cases (21 percent) 
• Important confirmatory data in 48 (21 percent) 
• Additional unrelated findings in 8 (3 percent) 
These findings are consistent with the results from earlier studies and support the continued use 
of routine electron microscopy. Diagnoses that commonly require electron microscopy included 
minimal change disease, focal and segmental glomerulosclerosis, membranoproliferative 
glomerulonephritis, membranous nephropathy, thin basement membrane disease and Alport 
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syndrome, postinfectious glomerulonephritis, HIV-associated nephropathy, amyloidosis, 
immunoglobulin deposition diseases, and fibrillary (immunotactoid) glomerulopathy. 
INDICATIONS  
The indications for performing a renal biopsy is determined in part by the presenting 
signs and symptoms4,5. The overall rate of native kidney renal biopsy (in number of procedures 
per million populations [pmp]) varies from over 250 pmp in Australia to less than 75 pmp in the 
USA6 . The renal biopsy rate is higher in adults than in children. 
These differences in renal biopsy rate are not driven by any differences in the spectrum of renal 
pathology, but rather by opinions regarding the value of the procedure in diagnosis, prognosis, 
and therapy. The results of the renal biopsy impact patient care in up to 60 percent of cases7,8. 
However, the utility of the biopsy may differ considerably based on the indication. 
Isolated nonnephrotic proteinuria – A renal biopsy generally is not performed in a patient who 
presents with low-grade proteinuria (less than 500 to 1000 mg/day), absence of glomerular 
hematuria, usually normal renal function, and an absence of clinical or serologic evidence of a 
systemic disease that can cause glomerulonephritis (eg, systemic lupus erythematosus, vasculitis, 
or a paraproteinemia). Some of these patients will have mild primary focal glomerulosclerosis, 
IgA nephropathy, or membranous nephropathy9; however, immunosuppressive therapy would 
not be indicated in this setting, since the prognosis with nonnephrotic proteinuria is often 
excellent. Other patients will have secondary focal glomerulosclerosis as a response to ischemic 
injury (as in nephrosclerosis) or to nephron loss (as in reflux nephropathy). 
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EVALUATION OF PROTEINURIA IN CHILDREN 
Introduction – Proteinuria as a marker of renal disease has been well established. The dilemma 
that faces the primary care physician is to differentiate the child with transient or other benign 
forms of proteinuria from the child with proteinuria from renal disease. 
PATHOPHYSIOLOGY AND CLASSIFICATION 
Normal protein excretion – Urinary protein excretion in the normal child is less than 100 
mg/m2 per day or a total of 150 mg per day. In neonates, normal urinary protein excretion is 
higher, up to 300 mg/m2, because of reduced reabsorption of filtered proteins. 
Approximately one-half of normal protein excretion consists of proteins secreted by tubular 
epithelium, mostly Tamm-Horsfall protein (uromodulin). The other half consists of plasma 
proteins including albumin, which accounts for approximately 40 percent of the total urinary 
protein, and low molecular weight proteins, such as beta-2 microglobulin and amino acids. 
Abnormal protein excretion – Urinary protein excretion in excess of 100 mg/m2 per day or 4 
mg/m2 per hour is considered abnormal in children. Nephrotic range proteinuria (heavy 
proteinuria) is defined as ≥ 1000 mg/m2 per day or 40 mg/m2 per hour. 
There are three main mechanisms of increased protein excretion: glomerular, tubular, and 
overflow proteinuria. 
Glomerular proteinuria – Glomerular proteinuria is due to increased filtration of 
macromolecules (particularly albumin) across the glomerular capillary wall. This may arise 
because of anatomical or functional lesions. 
Glomerular proteinurias are a common cause of proteinuria in children. They may result from 
glomerular disease (most often minimal change disease) or from nonpathologic conditions such 
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as fever, intensive exercise, and orthostatic (or postural) proteinuria, in which protein excretion is 
increased only in the upright position. 
Tubular proteinuria – Tubular proteinuria, which is less frequent, results from increased 
excretion of low molecular weight proteins such as beta-2-microglobulin, alpha-1-microglobulin, 
and retinol-binding protein. These molecules are normally filtered across the glomerulus and 
then largely reabsorbed in the proximal tubule. Interference with proximal tubular reabsorption, 
due to a variety of tubulointerstitial diseases, can lead to increased excretion of these smaller 
proteins. 
Tubular proteinuria often is associated with other defects in proximal tubular function, including 
glycosuria, proximal renal tubular acidosis with bicarbonate wasting, and phosphaturia. In 
Fanconi's syndrome, all four of these proximal tubular defects occur. 
Only albumin is detected by the urine dipstick, while tubular proteinuria is not detected by 
screening dipstick urinalysis. 
Overflow proteinuria – Overflow proteinuria results from increased excretion of low molecular 
weight proteins due to marked overproduction of a particular protein to a level that exceeds 
tubular reabsorptive capacity. Overflow proteinuria is not observed in children; it is primarily 
observed in adults with a plasma cell dyscrasia (eg, multiple myeloma) who overproduce 
immunoglobulin light chains. 
As with tubular proteinuria, overflow proteinuria with low molecular proteins will not be 
detected by screening dipstick urinalysis. 
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CAUSES OF PROTEINURIA IN CHILDREN 
Glomerular proteinuria 
Primary Causes Secondary Causes 
Minimal change disease 
Congenital nephrotic syndrome 
"Finnish-type" 
Mesangial sclerosis 
Focal segmental glomerular sclerosis 
IgA nephropathy (Berger's disease) 
Membranoproliferative glomerulonephritis 
Membranous nephropathy 
Alport syndrome 
Acute post-streptococcal glomerulonephritis 
Diabetes mellitus 
Systemic lupus erythematosus 
Henoch-Schönlein purpura 
 
Tubular Proteinuria 
Primary Causes Secondary Causes 
Cystinosis 
Dent's syndrome 
Wilson's disease 
Lowe's syndrome 
Polycystic kidney disease 
Mitochondrial disorders 
Heavy metal poisoning 
Acute tubular necrosis 
Tubulointerstitial nephritis 
Secondary to obstructive uropathy 
 
Among children with persistent proteinuria, a complete history and physical examination is 
needed, including measurement of the blood pressure. Initial laboratory evaluation includes renal 
function tests (blood urea nitrogen and creatinine), serum electrolytes, cholesterol, albumin, and 
total protein. Other tests such as renal ultrasound, serum complement levels (C3 and C4), ANA, 
streptozyme testing, hepatitis B and C serology, and HIV testing should be considered if 
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appropriate. A voiding cystourethrogram should be considered if there is an abnormal ultrasound 
with scarring or a history of fever suggestive of  urinary tract infections. 
If this initial evaluation is normal, the urine dipstick should be repeated on at least two additional 
specimens. If these subsequent tests are negative for protein, the diagnosis is transient 
proteinuria. 
If the proteinuria persists or if any of the studies are abnormal, the patient should be referred to a 
pediatric nephrologist. At this point, urinary protein excretion should be quantified by a timed 
collection, if obtainable. 
Indications for renal biopsy – The role of renal biopsy in a child with isolated asymptomatic 
persistent proteinuria is controversial10. Many nephrologists recommend close monitoring for 
those children with urinary protein excretion below 500 mg/m2 per day before considering a 
biopsy1. Monitoring should include assessment of blood pressure, protein excretion, and renal 
function. If any of these parameters shows evidence of progressive disease, a renal biopsy should 
be performed to establish a diagnosis. 
There are limited data on the results of renal biopsy in such children. 
In a retrospective review of 53 Japanese children with persistent isolated proteinuria, a 
significant glomerular disease was present in 25 (47 percent): 15 had focal segmental 
glomerulosclerosis (FSGS); four had IgA nephropathy, and three each had membranous 
nephropathy and diffuse mesangial proliferative glomerulonephritis without IgA deposition11. 
In a report of 461 Korean children with an abnormal urinalysis detected by school screening, 
only nine patients had isolated persistent proteinuria with protein excretion ≥2 g in a 24-hour 
collection12. Renal biopsy demonstrated changes consistent with minimal change nephrotic 
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syndrome in seven patients, and one case each of mesangial proliferative glomerulonephritis and 
membranous glomerulopathy. 
Symptomatic child – Clinical manifestations in the symptomatic child with proteinuria may be 
general and nonspecific (eg, fever, malaise, weight loss), non-urinary specific (rash, purpura, 
arthritis), or urinary specific (eg, edema, hypertension, renal insufficiency). The underlying 
disorder may be primarily renal in origin or secondary to a systemic process. Diagnostic 
categories include infections, rheumatologic and immunologic disorders, and primary and 
secondary glomerular and interstitial diseases of the kidney. 
• Children with heavy proteinuria and periorbital or peripheral edema must be evaluated 
promptly for nephrotic syndrome. The major manifestations of nephrotic syndrome are 
heavy proteinuria (protein excretion >1000 mg/m2 per day or spot urine Pr/Cr ratio >1.0), 
edema, serum albumin <2.5 g/dL, and hypercholesterolemia. Almost all such children 
have idiopathic nephrotic syndrome, and management decisions should be made in 
consultation with a pediatric nephrologist. 
Non-nephrotic children with persistent proteinuria who present with hypertension, an 
abnormal urinalysis, or an elevated plasma creatinine concentration should be referred to a 
pediatric nephrologist for further evaluation and possible renal biopsy. 
• In patients with an abnormal ultrasound or history of febrile urinary tract infections, a 
voiding cystourethrogram should be considered if there is an abnormal ultrasound with 
scarring or a history of febrile urinary tract infections 
Nephrotic syndrome – A renal biopsy typically is not indicated for the nephrotic syndrome in 
childhood. 
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In the absence of a systemic disease, it is quite likely that one of the three major causes of 
the idiopathic nephrotic syndrome is present: minimal change disease, focal glomerulosclerosis 
(accounting for over 80 percent of cases in adults and children) membranous nephropathy. 
Renal biopsies in children under the age of six years with nephrotic syndrome may not be 
necessary, as over 90 percent will have minimal change disease. The necessity of renal biopsy 
for nephrotic syndrome in older children, adolescents, and adults has been controversial, but we 
now have a better appreciation of the different therapies in these disorders. 
CLASSIFICATION : Children with nephrotic syndrome are  classified based upon whether or 
not there are signs of systemic disease or of an active urine sediment. 
• Primary nephrotic syndrome, which refers to nephrotic syndrome in the absence of an 
identifiable systemic disease. Within this category are patients with idiopathic nephrotic 
syndrome, who have bland sediment and no glomerular inflammation on renal biopsy 
and patients with primary glomerulonephritis, who have an active sediment and 
glomerular inflammation on renal biopsy. 
• Secondary nephrotic syndrome, which refers to nephrotic syndrome in the presence of an 
identifiable systemic disease. 
• Congenital and infantile nephrotic syndrome, which occur in children less than one year 
of age and can be either secondary (mostly due to infection) or primary. Two-thirds of 
nephrotic syndrome cases that occur during the first year of life and as many as 85 
percent of cases that occur during the first three months of life can be explained by 
mutations in one of four genes13. 
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Primary nephrotic syndrome – Primary nephrotic syndrome is defined as nephrotic syndrome 
in the absence of systemic disease. Within this category are two subgroups: 
• Disorders associated with a bland urine sediment and lack of glomerular inflammation 
on renal biopsy. Included in this group are idiopathic nephrotic syndrome.. 
• Nephritic disorders associated with an active urine sediment (red cells and cellular casts) 
and the presence of glomerular inflammation on renal biopsy. Included in this group 
are membranoproliferative glomerulonephritis and IgA nephropathy, which are 
discussed separately. 
Idiopathic nephrotic syndrome – Idiopathic nephrotic syndrome is the most common form of 
childhood nephrotic syndrome, representing more than 90 percent of cases before 10 years of 
age and 50 percent after 10 years of age14. Idiopathic nephrotic syndrome is defined by the 
association of the clinical features of nephrotic syndrome with renal biopsy findings of diffuse 
foot process effacement on electron microscopy and minimal changes (called minimal change 
disease [MCD]), primary focal segmental glomerulosclerosis (FSGS), or mesangial proliferation 
on light microscopy. It is unclear whether these three light microscopic patterns represent 
separate disorders or are a spectrum of a single disease process15. 
Most patients, particularly those who are young (<6 years of age), have histologic findings of 
MCD. The vast majority of patients with MCD (>90 percent) respond to glucocorticoid therapy16  
MCD can be clinically differentiated from those with other causes of childhood nephrosis. This 
was illustrated in a classic study from the International Study of Kidney Disease in Children 
(ISKDC) of 521 children (age range, 12 weeks to 16 years of age) who presented with primary 
nephrotic syndrome. The study was conducted in 24 centers in North America, Europe, and Asia 
between 1967 and 197414. Renal biopsies were obtained in all children. 
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Multivariate analysis demonstrated that clinical findings at presentation accurately differentiated 
children with MCD from those with other glomerular pathology14. These findings included: 
• Age younger than 6 years of age 
• Absence of hypertension 
• Absence of hematuria by Addis count 
• Normal complement levels 
• Normal renal function 
One exception to the age criterion is onset of nephrotic syndrome in the first year of life, 
particularly the first three months of life, which is much more likely to be due to a gene mutation 
and to be resistant to glucocorticoids13. 
Based upon these observations, an initial trial of glucocorticoid therapy is generally administered 
to children who are likely to have MCD based upon clinical diagnosis, thereby avoiding renal 
biopsy. Patients with idiopathic nephrotic syndrome are further classified based upon their 
response to empiric glucocorticoid therapy. 
Glucocorticoid-responsive nephrotic syndrome – The majority of children with idiopathic 
nephrotic syndrome are glucocorticoid-responsive (also referred to as glucocorticoid-sensitive 
nephrotic syndrome). In these patients, the most likely histologic lesion is MCD, although some 
patients with FSGS will also respond to glucocorticoid therapy15. Patients who are 
glucocorticoid-responsive have a favorable long-term outcome. 
• Glucocorticoid-resistant nephrotic syndrome – Approximately 25 percent of all children 
with nephrotic syndrome will not respond to glucocorticoid. The response rate is better 
in younger children, who are much more likely to have MCD. In an ISKDC study, only 
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about 10 percent of children less than 10 years of age failed to respond to 
glucocorticoids16. Patients with glucocorticoid resistant nephrotic syndrome have a 
worse prognosis than those who are glucocorticoid-responsive16,17. Some children with 
glucocorticoid-resistant nephrotic syndrome have genetic mutations of podocyte 
proteins. 
Secondary nephrotic syndrome – Secondary nephrotic syndrome is defined as 
nephrotic syndrome associated with systemic diseases or is secondary to another process 
that cause glomerular injury. Within this category are the same two subgroups as in 
primary nephrotic syndrome: 
• Disorders associated with a bland urine sediment and lack of glomerular inflammation 
on renal biopsy. Included in this group are some cases of membranous nephropathy (eg, 
due to lupus, penicillamine), secondary focal glomerulosclerosis due to nephron loss 
resulting from renal scarring or hypoplasia. 
• Nephritic disorders associated with active urine sediment (red cells and cellular casts) 
and the presence of glomerular inflammation on renal biopsy. A variety of disorders are 
included in this group. 
- Postinfectious glomerulonephritis and infective endocarditis. 
- Systemic lupus erythematosus. 
- Vasculitides such as Henoch-Schönlein purpura and rarely in Wegener's granulomatosis 
and microscopic polyangiitis. 
- Other causes include sickle cell disease, which is usually associated with secondary focal 
glomerulosclerosis, Alport syndrome and hemolytic uremic syndrome. 
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ETIOLOGY – Minimal change disease (MCD) is the most commonly seen histopathology of 
childhood nephrosis. In the previously mentioned ISKDC study of 521 children who presented 
with nephrotic syndrome without systemic disease between 1967 and 1974, the following 
findings were made based upon renal biopsy14. 
¾ Minimal change disease (MCD) – 77 % 
¾ Membranoproliferative glomerulonephritis (MPGN) – 8 % 
¾ Focal and segmental glomerulosclerosis (FSGS) – 7 % 
¾ Proliferative glomerulonephritis – 2 % 
¾ Mesangial proliferation – 2 % 
¾ Focal and global glomerulosclerosis – 2 % 
¾ Membranous glomerulonephropathy – 2 % 
Eighty percent of patients with MCD and 50 percent of patients with FSGS presented before six 
years of age. In contrast, none of the 39 patients with MPGN presented before six years of age. 
Subsequent studies have demonstrated an increasing prevalence of FSGS. Whether this is due to 
a true increase in prevalence or is a result of improved detection of the histologic changes 
consistent with FSGS on renal biopsy is unknown. Since the diagnosis of FSGS is made by the 
detection of one or more glomeruli with segmental glomerulosclerosis, one cannot be certain that 
a patient with an initial diagnosis of MCD does not actually have FSGS that was missed because 
of sampling error. 
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The following observations illustrate the range of findings: 
• In a retrospective study of 159 Canadian children with nephrotic syndrome who 
presented between 1985 and 2002, 115 patients (72 percent) had MCD, diagnosed by 
renal biopsy or response to glucocorticoid, and 29 children had FSGS (18 percent) 
diagnosed by renal biopsy18. The incidence of FSGS increased 2.5 fold during the last 
half compared to the first half of the study. 
• In another retrospective study of 152 patients from Texas with idiopathic nephrotic 
syndrome diagnosed between 1978 and 1997, 37 of the 105 patients who underwent 
renal biopsy had MCD (35 percent) and 33 (31 percent) had FSGS19. If one assumed 
that all 47 patients who did not undergo renal biopsy had MCD, then 55 and 22 
percent of the total group were estimated to have MCD and FSGS, respectively. FSGS 
was found in a greater percent of biopsies after 1990 compared to before (47 versus 23 
percent) and was the most common diagnosis for nephrotic syndrome in African 
American children (63 percent). 
In both of these studies, the incidence of FSGS may have been underestimated because all 
patients who did not undergo renal biopsy were presumed to have MCD and because FSGS can 
be missed on renal biopsy due to sampling error, since by definition the disease is focal (ie, only 
some glomeruli have sclerotic lesions on light microscopy). 
DIAGNOSIS – The diagnosis of nephrotic syndrome is made by fulfilling the following two 
defining characteristics: 
• Urinary protein excretion greater than 40 mg/m2 /hr 
• Hypoalbuminemia ( <  2.5 gm/ dL) 
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Although, edema is generally the presenting sign of nephrotic syndrome, the diagnosis is 
confirmed by the presence of nephrotic range proteinuria and hypoalbuminemia. 
EVALUATION OF MICROSCOPIC HEMATURIA IN CHILDREN: 
INTRODUCTION – Microscopic hematuria is a common finding in children. As illustrated in 
two large population-based studies, 3 to 4 percent of unselected school-age children between 6 to 
15 years of age had a positive dipstick for blood in a single urine sample 20,21. 
There is a long list of causes of microscopic hematuria, most of which are benign, especially in 
children with isolated asymptomatic microscopic hematuria. The dilemma that faces the clinician 
is to identify the child in whom hematuria caused by significant underlying disease. 
Isolated glomerular hematuria – In patients with asymptomatic microscopic hematuria (ie, 
persistent microscopic hematuria with dysmorphic red blood cells, negative "dipstick" for 
proteinuria, normal serum creatinine concentration, and normal blood pressure), the renal biopsy 
may not alter therapy, as such patients generally have a good prognosis. When biopsies are 
performed, they typically demonstrate either a normal kidney biopsy or one of three disorders: 
IgA nephropathy, hereditary nephritis (Alport syndrome), or thin basement membrane disease. 
Most patients with IgA nephropathy and thin basement membrane disease without proteinuria 
have a good long-term prognosis and, other than angiotensin converting enzyme inhibitors, there 
is no clear effective therapy for any of these conditions. 
As a result, a renal biopsy is not routinely performed to establish a specific diagnosis, at least in 
the United States, unless there is evidence of progressive disease, such as increasing proteinuria 
or a rising serum creatinine concentration22. In a prospective study of 276 native renal biopsies, 
for example, biopsy for isolated hematuria changed a management decision in only one of 36 
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patients4. However, a specific diagnosis may be desired by some patients for genetic counseling 
purposes, such as in Alport syndrome. 
DETECTION – Hematuria is defined by the presence of an increased number of red blood cells 
(RBCs) in the urine. Hematuria can either be visible to the naked eye (gross) or apparent only 
upon urinalysis (microscopic). Microscopic hematuria may be discovered as an incidental 
finding on an urinalysis prompted by urinary or other symptoms. 
Urinary dipstick – The most common screening test for hematuria is the urinary dipstick test for 
blood. The reagent strip that detects blood utilizes hydrogen peroxide, which catalyzes a 
chemical reaction between hemoglobin (or myoglobin) and the chromogen tetramethylbenzidine. 
Different shades of blue-green are produced according to the concentration of hemoglobin in the 
urine sample. These strips can detect 5 to 10 intact RBCs/µL, which roughly corresponds to a 
finding on microscopic examination of two to five RBCs per high-power field from the sediment 
of a centrifuged 10 to 15 mL urine sample. 
False-negative results can occur in the presence of formalin or high urinary concentration of 
ascorbic acid. False-positive results may occur with alkaline urine (ie, pH greater than 9) or 
contamination with oxidizing agents used to clean the perineum. 
Microscopic examination – A positive dipstick for hematuria is confirmed by a microscopic 
examination of the sediment of 10 to 15 mL of centrifuged fresh urine. Microscopic hematuria is 
defined as the presence of more than five RBCs per high-power field (40x magnification)23,24. 
The microscopic examination is the gold standard for the detection of microscopic hematuria. 
Dipsticks for hemoglobin are as sensitive as the urine sediment examination, but result in more 
false-positive tests. In comparison, false-negative dipstick tests are unusual; as a result, a 
negative dipstick reliably excludes abnormal hematuria. 
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The procedures for obtaining and processing urine samples in children are reviewed separately. 
Glomerular versus nonglomerular bleeding – Urinalysis including microscopic examination 
may identify a potential site of bleeding (glomerular versus nonglomerular) and aid in 
determining the underlying cause. The identification of the glomeruli as the source of blood is 
important both prognostically and to optimize the subsequent diagnostic evaluation. 
Signs of glomerular bleeding in children with microscopic hematuria include the following: 
• Red cell casts (pathognomonic for glomerular disease) 
• Protein excretion greater than 100 mg/m2 at a time when there is no gross bleeding. The 
optimal method is obtaining a first morning sample to determine the protein to creatinine 
ratio because it excludes orthostatic proteinuria, a normal variant. 
• Red blood cells (RBCs) having a dysmorphic appearance25. 
Although helpful if present, the absence of these findings does not exclude glomerular disease. 
Morphologic study of urinary RBCs, particularly with a phase-contrast microscope, may be 
helpful in distinguishing glomerular from nonglomerular bleeding. The presence of more than 30 
percent dysmorphic RBCs or of more than 5 percent of a specific form named an "acanthocyte" 
is highly suggestive of glomerular hematuria. However, confident identification of such cells 
requires expertise in urinalysis. 
In nonglomerular hematuria, microscopic examination demonstrates urinary RBCs with a 
uniform normal size and shape. However, hypercalciuria, a nonglomerular cause of hematuria, 
can be associated with dysmorphic red blood cells but not red cell casts. 
EPIDEMIOLOGY – Several population-based studies of unselected school-age children have 
shown that the prevalence rate for microscopic hematuria detected in a single urine sample is 3 to 
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4 percent, which falls to 1 percent or less for two or more positive samples20,21,26. Among the 1 
percent of children with two or more positive urines for hematuria, only one-third have persistent 
hematuria, defined as a positive repeat test after six months20,21. 
The combination of hematuria and proteinuria is less common with a prevalence rate of less than 
0.7 percent in unselected school-age children in a single urine sample20,21. 
ETIOLOGY – Both benign and serious conditions can cause microscopic hematuria in children. 
The most common causes of persistent microscopic hematuria include glomerulopathies, 
hypercalciuria, and nutcracker syndrome23. 
• IgA nephropathy – IgA nephropathy is diagnosed by renal biopsy with mesangial IgA 
deposits on immunofluorescence study  There is often a history of gross hematuria 
preceded by an upper respiratory tract or gastrointestinal illness and usually a negative 
family history of renal disease.  
• Alport syndrome – Classic Alport syndrome (hereditary nephritis) is a recessive X-linked 
disorder that is typically seen in males and is often accompanied by high-frequency 
sensorineural hearing loss, ocular abnormalities including anterior lenticonus, and, over 
time, progressive renal failure  Heterozygous carrier-females also can have hematuria, 
but do not have progressive renal disease. 
• Thin basement membrane disease (TBM) – TBM, also called benign familial hematuria, 
is an autosomal dominant condition. Kidney biopsy reveals an isolated thinning of the 
glomerular basement membrane on electron microscopy . In many cases, TBM disease is 
the heterozygous form of autosomal recessive Alport syndrome involving the COL4A3 
or COL4A4 genes; two abnormal genes are required for the Alport phenotype. 
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• Postinfectious glomerulonephritis – In children with poststreptococcal 
glomerulonephritis, hematuria generally resolves within three to six months after the 
presentation. 
• Hypercalciuria – Hypercalciuria, defined in children as a urine calcium/creatinine ratio 
>0.2 (mg/mg) in children older than six years of age, has been associated with 
asymptomatic microscopic hematuria. In studies performed in the United States, the 
prevalence has ranged from as low as 11 percent in the Northeast27 to as high as 35 
percent in the South28,29. Thus, the association between hypercalciuria and hematuria may 
be more common in areas where there is a higher prevalence of nephrolithiasis. 
EVALUATION – The diagnostic evaluation depends upon the clinical presentation, which falls 
into the following three categories: 
• Asymptomatic isolated microscopic hematuria 
• Asymptomatic microscopic hematuria with proteinuria 
• Symptomatic microscopic hematuria . 
Distinguishing extraglomerular from glomerular hematuria 
 Extraglomerular Glomerular 
Color (if macroscopic) Red or pink Red, smoky brown, or "Coca-Cola" 
Clots May be present Absent 
Proteinuria Usually absent May be present 
RBC morphology Normal Dysmorphic 
RBC casts Absent May be present 
Asymptomatic isolated microscopic hematuria – As noted above, asymptomatic isolated 
microscopic hematuria (ie, no proteinuria) is present in 3 to 4 percent of unselected school-age 
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children20,21,26. However, significant clinical disease is rarely detected. This was illustrated in a 
1979 study of an unselected population of 8954 children who were screened for hematuria.  
The following  approach can be considered for children with asymptomatic isolated microscopic 
hematuria based upon the available literature20,21,23,45. 
• Evaluation including blood pressure measurement and a urinalysis should be performed 
weekly for two weeks. One should ensure that there is no exercise prior to obtaining the 
urine sample, since vigorous exercise can induce hematuria. A thorough evaluation 
should be undertaken only if the patient becomes symptomatic or develops hypertension, 
gross hematuria, or proteinuria. 
• If isolated hematuria persists, obtain a urine culture. If the culture is positive, treat with 
appropriate antibiotics. 
• If the patient remains asymptomatic and the urine culture is negative, continue to observe 
the patient every three to six months including physical examination with blood pressure 
measurement and urinalysis. 
• If the asymptomatic isolated hematuria persists for one year, the following subsequent 
evaluation should be performed: 
- Measure urine calcium/creatinine ratio for hypercalciuria. Hypercalciuria, defined as a 
urine calcium/creatinine ratio >0.2 (mg/mg), has been associated with asymptomatic 
microscopic hematuria. 
There is disagreement as to whether children with hypercalciuria have an increased 
likelihood of a family history of nephrolithiasis and whether hypercalciuria leads to renal 
stones27,28,29. Although lowering urinary calcium excretion with a thiazide diuretic can lead to 
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resolution of the hematuria29, there is at present no consensus on the further evaluation or 
treatment of children with isolated microscopic hematuria who have hypercalciuria. 
Asymptomatic microscopic hematuria and proteinuria – The combination of hematuria and 
proteinuria is significantly less common than either isolated proteinuria or hematuria. Although 
asymptomatic hematuria with proteinuria has a prevalence rate of less than 0.7 percent in 
unselected school-age children, it is associated with a higher risk for significant renal 
disease20,21,24,30. 
Evaluation of these patients starts with measurement of serum creatinine and quantification of 
proteinuria either by a 24-hour urine collection or determination of the urine protein-to-creatinine 
ratio on a first morning urine sample. 
• If protein excretion is >4 mg/m2 per hour or if in a first morning urine specimen, the 
urine protein-to-creatinine ratio is >0.2 mg protein/mg creatinine in children older 
than 2 years of age and >0.5 mg protein/mg creatinine in younger children, the patient 
should be referred to a pediatric nephrologist (or a clinician with expertise in the care 
of children with renal disease) since it is likely that there is significant renal disease. 
• If protein excretion is less than the above values, the patient should be reevaluated in 
two to three weeks. 
- If the hematuria and proteinuria have resolved, no further evaluation is needed. 
- If there is only asymptomatic microscopic hematuria, the patient is monitored in the same 
fashion as those described above with asymptomatic isolated microscopic hematuria. 
- If proteinuria is persistent the patient should be referred to a pediatric nephrologist (or a 
clinician with expertise in the care of children with renal disease) for further evaluation. 
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- Patients with significant proteinuria or an elevated serum creatinine at baseline, or 
persistent proteinuria at follow-up should be referred to a pediatric nephrologist (or a 
clinician with expertise in the care of children with renal disease) because they are likely 
to have renal disease. Further assessment should include microscopic examination of the 
urine by an experienced clinician, serum creatinine, C3, C4, albumin, and complete blood 
count. Depending upon the findings, other tests that may be considered include ASO titer, 
streptozyme testing, antinuclear antibody testing, imaging, and renal biopsy. 
Symptomatic microscopic hematuria – The evaluation of symptomatic microscopic hematuria 
is directed by the patient's symptoms and clinical findings. This category is the most challenging 
because it encompasses a wide range of diseases with varying clinical presentations23,31. The 
clinical manifestations may be nonspecific (eg, fever, malaise, weight loss), extrarenal (eg, rash, 
purpura, arthritis), or related to kidney disease (eg, edema, hypertension, dysuria, oliguria). 
The presence of nonspecific or extrarenal manifestations suggests a systemic process such as 
lupus nephritis or Henoch-Schönlein purpura. Renal causes of symptomatic microscopic 
hematuria include glomerular or interstitial diseases of the kidney, lower urinary tract disease, 
nephrolithiasis, tumors, and vascular disease. 
The diagnosis may be evident and straightforward from the history and physical examination. 
The urinalysis can be helpful in differentiating between glomerular and nonglomerular causes of 
bleeding. 
Indications for renal biopsy – A renal biopsy is not usually performed for isolated microscopic 
hematuria. However, biopsy should be considered if there is evidence of substantial or 
progressive disease as manifested by an elevation in the creatinine concentration, significant 
proteinuria, or an otherwise unexplained rise in blood pressure even when the values remain 
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within the normal range. Biopsy also may be considered in the child with persistent glomerular 
hematuria, in whom the parents are worried about the diagnosis and prognosis. In addition, a 
kidney biopsy may be considered in a child with microscopic hematuria and a family history of 
kidney failure in early adulthood in a first order relative. 
Patients with clear evidence of poststreptococcal glomerulonephritis represent an exception to 
these general recommendations, since gradual spontaneous recovery is the rule, although 
proteinuria may gradually return to normal over many years. 
Acute nephritic syndrome – Hematuria, cellular casts, proteinuria, and frequently hypertension 
and renal insufficiency – is often caused by a systemic disease that requires a renal biopsy to 
establish the diagnosis and guide treatment. However, there are situations in which the initiation 
of therapy is required while awaiting the renal biopsy. Examples include microscopic 
polyangiitis, Wegener's granulomatosis, or anti-GBM disease. These are disorders that are 
associated with rapidly progressive glomerulonephritis and, in the appropriate clinical setting, 
are suggested serologically by the presence of circulating antineutrophil cytoplasmic antibodies 
(ANCA) or anti-GBM antibodies. 
The reason for a biopsy is variable in lupus nephritis. Patients with acute renal insufficiency and 
an active sediment may have any number of lesions and require a renal biopsy to establish a 
diagnosis, determine prognosis, and guide therapy. 
Another indication for renal biopsy is an intermediate clinical presentation – mild proteinuria and 
hematuria, or nephrotic syndrome with a bland sediment. In this setting, the diagnosis may be 
focal or diffuse proliferative disease or membranous lupus, each of which may require different 
forms of therapy. A repeat biopsy may also be performed for late progression of the disease to 
distinguish between active lupus (which may require immunosuppressive therapy) and scarring 
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of previous inflammatory injury (which may warrant antihypertensive therapy with an 
angiotensin converting enzyme inhibitor). 
Unexplained acute renal failure – The most common causes of acute renal failure – prerenal 
disease, acute tubular necrosis, and urinary tract obstruction – can be diagnosed without renal 
biopsy. Biopsy is indicated in those settings in which the diagnosis is uncertain, as may 
sometimes be the case with acute interstitial nephritis secondary to drugs9. By comparison, 
patients with small kidneys or slowly progressive chronic renal failure over a period of years are 
generally not biopsied since there is little likelihood of finding a treatable disease. 
OVERVIEW OF SPECIFIC ISSUES IN PAEDIATRIC RENAL BIOPSY PATHOLOGY 
Congenital/infantile nephrotic syndrome 
Children presenting with nephrotic syndrome in the first 3 or 6 months of life are 
considered to be suffering from some form of CNS, and additional cases will present during the 
infantile period. There are traditionally two major pathomorphological subtypes of CNS: 
Finnish-type (associated with nephrin gene mutations) and French-type, now more commonly 
referred to as diffuse mesangial sclerosis (associated with WT1 or unknown mutations). 
It is apparent that infants with congenital/ infantile nephrotic syndrome may also exhibit a 
variety of other glomerulopathies, including otherwise unspecified diffuse mesangial 
proliferative glomerulonephritis and idiopathic primary FSGS variants, in addition to the 
traditional CNS subtypes , some of which may respond to treatment with angiotensin-converting 
enzyme inhibitors32. CNS may rarely be associated with other specific 
aetiologies such as congenital infections including cytomegalovirus (with a diffuse mesangial 
sclerosis pattern in association with viral inclusions, which may respond to antiviral treatment)33, 
syphilis and toxoplasmosis34. 
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Furthermore, it is now apparent that these categories of disease, including the apparently 
well-described Finnish-type CNS and diffuse mesangial sclerosis, may be both morphologically 
and genetically heterogeneous. Classical Finnish-type CNS is an autosomal recessive disorder 
caused by mutations in the nephrin gene (NPHS1), a component of the glomerular slit 
diaphragm, and more than 50 mutations have been reported, including two predominant 
nonsense mutations in Finnish patients and a range of missense, nonsense and splice-site 
mutations, as well as deletions and insertions, predominantly in non-Finnish groups35,36. 
Additional mutations of other genes also involved in slit diaphragm structure, such as podocin, 
are now recognised as being of increasing importance in determining the phenotype of CNS37. 
CNS may also rarely be a presentation of other systemic disorders, such as mitochondrial 
respiratory chain deficiency, in which the pathological phenotype may mimic Finnishtype CNS 
but without associated nephrin mutations38, and infantile lupus39. From a practical perspective, 
the diagnostic pathologist faced with a biopsy to interpret should be aware that the classical 
‘textbook’ features of these conditions may not be readily apparent in a needle-core biopsy 
obtained early in the disease course, and conversely, with disease progression, secondary 
glomerular and tubulointerstitial changes may also make the specific diagnosis difficult in such 
core biopsy material. The main aim of biopsy in this setting is therefore to exclude other 
subtypes of nephrotic-associated glomerulopathy, which may be amenable to therapeutic 
intervention, and to make a specific diagnosis where possible. 
Finnish-type CNS is classically characterised by glomeruli that are initially morphologically 
unremarkable but may develop mild dilation of Bowman’s space, with associated scattered 
characteristic tubular microcyst formation owing to dilation of the proximal tubular components.  
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With disease progression, cyst formation may become more prominent and there are 
superimposed secondary changes of glomerulosclerosis, tubular atrophy and interstitial fibrosis, 
which are often readily apparent in cases coming to nephrectomy. In contrast, diffuse mesangial 
sclerosis is characterised by widespread glomerular sclerosis, with many glomeruli appearing 
small and shrunken, many being virtually replaced by hyaline nodules. In this setting, the 
peripheral glomeruli are most severely affected, in contrast to idiopathic FSGS in which the deep 
juxtamedullary glomeruli are characteristically most severely involved. 
The main aim of biopsy in this setting is to  determine the underlying diagnosis in order 
to direct further therapy and assess prognosis, the main differential diagnosis being MCD versus 
other causes of paediatric nephrotic syndrome such as idiopathic FSGS, and other rarer entities40. 
Since the deep juxtamedullary glomeruli are initially preferentially affected in primary FSGS, 
comment should be made on whether the biopsy includes this deep cortical zone, particularly in 
cases in which no histological abnormalities are seen on light microscopy. Furthermore, it should 
be remembered that any area of tubular atrophy is a significant finding in a paediatric renal 
biopsy, and in this context such a finding should raise the suspicion of an associated focal 
segmental sclerotic lesion, so serial sections should be examined. It is noteworthy that, in 
contrast to adult practice, primary membranous nephropathy is extremely uncommon in 
childhood, although well reported. The histological features are identical to those seen in adults, 
with secondary membranous change in the setting of lupus nephritis being more frequent in 
centers dealing with patients with autoimmune disease. 
For example, in two studies including more than 300 children biopsied for steroid-
resistant or atypical nephritic syndrome, FSGS was diagnosed in around 40%, followed by 
minimal-change nephropathy (20–30%), MPGN (15%), mesangial proliferative (10%) and 
membranous (5%). In younger children, however, MCD was the most common entity, whereas 
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FSGS predominated in the older children41,42.  In addition, it has been reported that the frequency 
of FSGS is increasing, but it remains uncertain whether this represents a true increase in 
prevalence or is simply a consequence of changing biopsy indications, referral practices or 
criteria for diagnosis on the part of pathologists. Other specific morphological causes of nephritic 
syndrome are unusual, but it should be noted that both familial and HIV-associated collapsing 
glomerulopathy are recognised in childhood with similar histological features to the adult 
counterpart (collapsed, sclerosed glomeruli with prominent glomerular epithelial cells and 
associated tubular dilation), and poor renal prognosis with rapid progression. Other conditions 
that may present with nephrotic syndrome (usually mixed nephritic/ nephrotic) in this group of 
patients are dense deposit disease, a diagnosis that requires electron microscopic examination for 
definitive confirmation  and membranoproliferative glomerulonephritis, the features of which are 
identical to those in adults. 
A prediction of the long-term response to therapy and the outcome in paediatric nephrotic 
syndrome is difficult, the major prognostic factor overall being the initial response to steroids40. 
In those undergoing renal biopsy, the presence of FSGS is associated with a, increased risk of 
progression to renal failure, but within this subgroup there is a relatively poor association 
between the histopathological findings and the prediction of outcome in an individual patient. In 
general, the extent of glomerulosclerosis and chronic tubulointerstitial changes is most strongly 
associated with subsequent adverse outcome, but other features such as associated immune 
deposition or mesangial expansion appear to show no consistent relationship with disease 
progression and outcome43. After proteinuria, apparently isolated haematuria is next most 
common indication for renal biopsy in childhood. The most frequent diagnoses in this group of 
patients include congenital abnormalities of the glomerular basement membranes, IgA 
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nephropathy and other glomerulonephritides, most of which are associated with coexisting 
proteinuria or other manifestations. 
Since Alport syndrome and TGBM nephropathy are relatively common in this context, it 
is obviously essential that all such biopsies undergo routine electron microscopic examination. 
Although ultrastructural examination is diagnostic, it should be noted that the characteristic 
‘basketweave’ basement membrane change of Alport syndrome may not always be present in 
children, and the only finding initially may be diffuse thinning of the basement membrane. 
Hence the possibility of Alport syndrome should not be excluded on a single renal biopsy finding 
of apparently isolated basement membrane thinning, particularly if other suggestive clinical or 
morphological features are present. Furthermore, there may be a variation in basement 
membrane thickness, and the subjectively thinned areas should be targeted. Although normal 
ranges are available for glomerular basement membrane thickness by age and sex in childhood44, 
it is suggested that each centre use its own derived age-related normal ranges as there may be 
variability in measurement techniques and processing methods. Acute renal failure In the setting 
of acute renal failure in childhood, the most common associated conditions of those children who 
come to biopsy are vasculitic, such as Henoch–Scho¨nlein nephritis and Wegener’s 
granulomatosis, systemic diseases such as lupus erythematosus  and other glomerulonephritides 
such as MPGN and diffuse endocapillary proliferative post-infectious glomerulonephritis. 
Acute interstitial nephritis may also occasionally be biopsied in this setting, particularly if 
the features and clinical history are atypical, and thrombotic microangiopathies such as 
haemolytic uraemic syndrome are also encountered. The pathological features of these 
conditions are essentially identical to those described in the adult literature. 
In addition to establishing the primary diagnosis, the biopsy should be processed urgently in this 
clinical setting as treatment may depend upon the extent of disease activity, particularly in the 
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vasculitic conditions in which the extent and type of crescents present may be used to stratify 
further clinical management protocols. It should be noted, as above, that children with nephrotic 
syndrome may develop acute oliguria when dehydrated, and acute renal deterioration in such 
patients should also raise the possibility of superimposed renal vein thrombosis. 
Childhood Lupus Nephritis: 
Systemic lupus erythematosus (SLE) is an autoimmune disease that involves multiple organs, 
causing severe morbidity and mortality. While the incidence of childhood SLE is relatively low, 
renal involvement appears to be more common and severe in children than in adult SLE 
patients45,46,47. It has been reported that more than 70% of children diagnosed with SLE develop 
lupus nephritis (LN) at the early stage of the disease47,48,49. Recently, improved treatment 
outcomes for children with LN have been reported. Pediatric studies on LN showed a 5-year 
patient and renal survival rate of more than 83% and 63%, respectively50,51,52,53. These results 
might be due to more extensive use of cytotoxic agents in addition to corticosteroids (CSD) in 
severe LN cases54,48,49. However, it has not been established which cytotoxic agent is most 
responsible for this improvement in renal and patient survival in pediatric LN. 
After the reports from the National Institutes of Health (NIH) study group55,56 intravenous 
cyclophosphamide (CPM) pulse therapy has been widely accepted as the ‘gold standard’ 
treatment for diffuse proliferative LN, not only in adults but also in children. However, recent 
controlled trials have been unable to demonstrate the superiority of prolonged CPM pulse 
therapy over other immunosuppressants added to the CSD treatment in the management of 
severe LN57,58,59. Likewise, while some pediatric reports claimed better renal survival rates in 
patients undergoing long-term CPM pulse therapy51, other reports did not60.  
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AIMS AND OBJECTIVES OF THE STUDY: 
 
 
1. To study the distribution of  various  renal diseases in pediatric age group in our center 
2. To analyze patient characteristics, clinical and biochemical parameters among each group 
of biopsy proven renal diseases. 
3. To study the various modality of treatment and its out come  among these patients. 
 
PATIENTS AND METHODS: 
 
This study included all paediatric patients (age  between 0 -18 years) with biopsy proven 
renal disease between 1997 -2006 in Christian Medical College, Vellore, a tertiary referral center 
in South India. 
Inclusion criteria: Patients between 1 month -18 years of age & Biopsy proven renal diseases 
Exclusion criteria: Patients more than 18 years of age & Those patients who have undergone 
renal transplantation 
Evaluation and Study design: 
First, the type of renal disease based on biopsy was categorized.  Among each group of 
renal disease, detailed demographic parameters of each patient was documented and patients 
were analyzed separately to look for multiple clinical and biochemical parameters. The light 
microscopic picture, response rate, relapse rate and medications used were separately analyzed 
for each group of diseases. Patients less than 10 years of age underwent biopsy procedure under 
general anaesthesia.  
Statistical analysis:   
Data were analyzed using SPSS version 15 Inc. (Chicago, USA). Standard statistical 
methods for assessment on proportions, percentages and measures of central tendencies (mean, 
SD, median and range).   
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DEFINITIONS : 
International Study of Kidney diseases in Children. 
Nephrotic syndrome is defined as heavy proteinuria (> 40 mg / hr /m2) determined quantitatively 
on an overnight collection of urine, accompanied by hypoalbuminaemia (2.5 g/dl).  
Proteinuria is considered to be in the nephrotic range when the 
9 urine protein is 3+/4+ on a dipstick test, 
9 spot protein/creatinine ratio >2 mg/mg, or 
9 urine albumin >40 mg/m2/ hr (on a timed sample). 
OUTCOME MEASURES: 
¾ Response – reduction of urinary excretion of protein to <4 mg/h/m2 or albustix of 0 
to trace for 3 consec. days 
¾ Relapse – appearance of proteinuria ≥ 40 mg/h/m2 or albustix of ≥ 2+ for 3 consec. 
days 
¾ Initial Responder – patient who responds during 8 weeks of initial regimen 
¾ Initial Non responder – patient who failed to respond during the first 8 weeks of 
treatment 
¾ Late Responder – Initial nonresponder who responded after some time after the first 
8 weeks of prednisolone therapy 
¾ Late Non responder – Initial responder who subsequently failed to respond 
¾ Early Relapser – Initial responder who relapsed during the initial 8 weeks therapy 
itself 
¾ Frequent Relapser – An initial responder who has 2 or more relapses within first 6 
months of initial response. 
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RESULTS: 
¾ Duration of study – Between January 1997 and December 2006 
¾ Total no of biopsies – 1480. 
¾ Data analyzed – 887 (583 excluded due to unavailability of data) 
¾ Age  group –  Between 1 Month to 18 years. 
Total number of paediatric renal biopsies done at  CMC Vellore during the time period 1997 
and  2006 were 1480.Out of which 887 patients data  were analyzed. In the  others the 
records were not available. The age group were from 1 month upto  to 18 years of age. 
 
 
 
 
 
 
 
 
 
Figure 1           Figure 2 
The mean age was 11.62  ± 5.12 yrs with range of 1-18 yrs. Majority of the children were above 
12 years of age. Male children constituted 554 (62.5 %). 
Gender (n=887)
Male 
554
(62.5%) 
333 
(37.5%)
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Distribution of Biopsy (Year wise) n-887
 
Figure 3: Shows the year wise distribution of renal biopsy.  
 
Table 1: Various clinical syndromes 
Clinical Syndromes (n=887) Percentage 
Nephrotic  Syndrome ( n- 611) 68.6% 
Nephritic Syndrome ( n- 211) 25.3% 
Rapidly progressive renal failure ( n- 22) 2.5% 
End Stage Renal Disease (unknown etiology),( n-14) 1.6% 
Asymptomatic hematuria ( n- 15) 0.8% 
Acute Renal failure (n- 4) 0.4% 
Subnephrotic proteinuria ( n- 2) 0.2% 
Others (Alports syndrome), ( n- 8) 0.6% 
 
36 
 
Table -2: Different histopathological diagnoses with clinically diagnosed 
Nephrotic Syndrome.  
 
Table 3: Various histopathological diagnoses with clinically diagnosed 
Nephritic Syndrome.         
Nephritic syndrome (n=211) Number (%) 
Lupus nephritis 80 (37.9%) 
Acute Proliferative GN 51 (24.1%) 
IgA  Nephropathy 38 (18%) 
Mesangial proliferative GN 32 (15.1%) 
Crescentic GN, FSGS,Vasculitis, AIN, HUS, 
End stage   kidney   disease. 
10 (0.47%) 
Nephrotic syndrome  (n=611) Number (%) 
Minimal change disease 291 (47.6%) 
Mesangial proliferative GN( non IgA) 111 (18%) 
Focal Segmental Glomerulosclerosis 55 (9%) 
Diffuse mesangial hypercellularity 53 (8%) 
Proliferative GN 24 (3.9%) 
Membranous GN 23 (3.7%) 
Mesangial proliferative  IgA  Nephropathy 20 (3.2%) 
Lupus nephritis 15 (2.4%) 
Membrano  proliferative GN 7 (1.1%) 
Vasculitis,granulomatous interstitial  nephritis, 
End stage   kidney   disease. 
5 (0.8%) 
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Table -4: Various histopathological diagnoses with clinically diagnosed Rapidly 
Progressive Renal Failure. 
 
Rapidly Progressive Renal Failure (n=22) Number (%) 
Crescentic GN 12 (54.54%) 
Proliferative GN 4 (18.18%) 
FSGS 2 (9.09%) 
Mesangial proliferative GN, IgA nephropathy, AIN, 
End stage kidney disease 
1 each  
 
Fig 4 
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Minimal change disease was 303(34.16%),Mesangial proliferative GN was 146 
(16.45%), Lupus nephritis was 98(11.05%), Proliferative glomerulonephritis was 81(9.13%), 
IgA nephropathy  was 61 (6.87%), Focal segmental glomerulosclerosis  was 59(6.65%), Diffuse 
mesangial hypercellularity was 53(5.97%), Membranous glomerulonephropathy was 
24(2.70%),Crescentic glomerulonephritis was 15(1.69%), Membrano proliferative 
glomerulonephritis  was 8(0.9 %),Hemolytic uremic syndrome was 5 (0.56 %),Vasculitis was 
3(0.33 %), Acute interstitial nephritis was 3 (0.33%), Acute tubular necrosis  was 2(0.22 %), 
granulomatous interstitial nephritis was 3(0.33%),End stage etiology of unknown etiology were 
17(1.92 %), Inadequate sample was 2 (0.22%).  
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Table 5: Geographic distribution of patients from different states of 
India. 
Sl No State No of patients Percentage 
1 West  Bengal 344 38.8 
2 Tamil Nadu 148 16.7 
3 Jharkhand 87 9.8 
4 Bihar 49 5.5 
5 Kerala 46 5.2 
6 Bangladesh 43 4.8 
7 Assam 28 3.2 
8 Andhra pradesh 26 2.9 
9 Orissa 20 2.3 
10 Arunachal pradesh. 11 1.2 
11 Karnataka 10 1.1 
12 Chhatisgarh 9 1.0 
13 Madhya pradesh 9 1.0 
14 Bhutan 9 1.0 
15 Tripura 8 0.9 
16 Meghalaya 7 0.8 
17 Mizoram 7 0.8 
18 Manipur 6 0.7 
19 Nepal 7 0.8 
20 Uttar pradesh 4 0.5 
21 Maharastra 2 0.2 
22 Nagaland 2 0.2 
23 Maldives 2 0.2 
24 C handigarh 1 0.1 
25 Jammu & kashmir 1 0.1 
26 Sikkim 1 0.1 
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DISTRIBUTION ,DEMOGRAPHIC DETAILS,TREATMENT & OUTCOME  OF 
VARIOUS TYPES OF DISEASES IN CHILDHOOD. 
Table 6:    Different characteristics  of  Minimal Change Disease 
Minimal change disease (MCD) n = 303 Characteristics 
Gender (M:F) 3:1 
Age (Mean ± SD, Range) 8.48 ± 4.7, 1-18 
Nephrotic: Subnephrotic 184: 92 (valid 276) 
Time for remission (Median days; range) 209, 8 – 3408 
Follow up in days (Median; Range) 464, 28 – 3618 
Creatinine (Mean ± SD, Range) 0.58 ± 0.24, 0.3 – 2.9mg% 
24 Hr Urine protein (Median, Range) 639.5.6 mg – 19.5 gm 
Serum albumin (Mean ± SD, Range) 2.7 ± 1.2, 0.3 – 4.9gm 
Hypercholesterolemia 138 (74.6%) valid for 185 pt only 
 
Among the various diseases in childhood minimal change disease was the majority, contributing 
to 34.16%. 
Table 6: shows that the mean age was 8.48 ± 4.7(1-18 years), male children were the maximum 
in number.184 patients had nephrotic range proteinuria.  The mean serum albumin was 2.7 ± 1.2 
(0.3 – 4.9 gm), median 24 hr urinary protein was 639 mg. The median time for remission was 
209 days. The median duration of follow up was 464 days. 
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Table 7: Treatment received (before presenting to this institute)  
Drug Frequency (N) Percentage (%) 
No Treatment 41 13.5 
Prednisolone 250 82.5 
Prednisolone + levamisole 4 1.3 
Prednisolone + Cyclophosphamide 4 1.3 
Cyclophosphamide 1 .3 
Prednisolone + Azathioprine 1 .3 
Prednisolone + Cyclophosphamide + Azathioprine 1 .3 
Levamisole 1 .3 
Total 303 100.0 
 
Table 7 shows the distribution of patients who had been treated with different drugs before 
presenting to us. Out of 303 cases, 250 (82.5%) patients were treated with prednisolone whereas 
4 patients (1.3%) each were treated with  a combination of prednisolone with cyclophosphamide 
and prednisolone and levamisole. Forty one (13.5%) patients had not received any treatment 
before presenting to us. 
 
 
Table -8: Various histological variant of minimal change disease by light 
microscopy in this study. 
 
Disease Frequency Percent 
MCD 30 9.9 
MMH 263 86.8 
MMH + AIN 1 0.3 
MMH + Interstitial changes 4 1.3 
MMH + Incipient sclerosis 5 1.7 
Total 303 100.0 
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Figure 5: Outcome of children with Minimal change disease 
 
             
             
             
             
             
      
 
 
 
             
             
             
             
  
 
 
CR – Complete remission ; PR – Partial remission ; SR – Sustained remission;  SPR – Sustained 
partial remission ; NR – No remission;   No F/U – No follow up. 
 
Out of 303 children with MCD, 199 (65.67%) patients achieved complete remission, 14 (4.62%) 
patients achieved partial remission, 48 ( 15.84%) patients did not achieve remission, 13 (4.29%) 
patients had relapse, 39 (2.97 %) patients did not have follow up after biopsy, however another 
59( 19.47%) patients who were in remission during biopsy also did not follow up after biopsy. 
Among the complete remission group 109 (54.77%) patients were only on steroid during the first 
revisit after biopsy. Rest were on various medication like, 47(23.61%) patients were on 
combination of steroid & cyclophosphamide. 2 patients were on steroid & tacrolimus,10 (5.02%) 
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patients were on steroid & cyclosporine,16 (8.04%) patients were on levamisole,1 patient was 
only on cyclosporine.6 patients were not on any medication. 
On final follow up 65 patients were in sustained remission and 10 children had relapse.  
Out of 48 patients which did not achieve remission 44(14.52%) patients were only on steroid.  
3 patients were on combination of steroid & cyclophosphamide, 1 patient was on only 
cyclophosphamide. 
 
Table 9: Various characteristics of diffuse mesangial hypercellularity. 
Diffuse Mesangial Hypercellularity (DMH)  (n =53) Characteristics 
Gender (M:F) 1.5 : 1 
Age (Mean ± SD, Range) 9.3 ±5.12, 0.1-18 
Nephrotic: Subnephrotic 26: 22 (valid 48) 
Time for remission (Median days, range) 212, 59 – 1294 
Followup in days (Median Range) 106.8, 71 – 2693 
Creatinine (Mean ± SD, Range) 0.61 ± 0.16, 0.3 – 1.1mg% 
24 Hr Urine protein (Median, Range) 1300, 10mg – 18.4 gm 
Serum albumin (Mean ± SD, Range) 2.24 ± 1.11, 0.8 – 4.7gm 
Hypercholesterolemia 29 (85.3%) valid for 34 pt only 
 
Table 9 shows the various characteristics of diffuse mesangial hypercellularity. The mean age 
was 9.3 ± 5.12 (0.1 – 18yr),male children were the maximum in number. The mean serum 
albumin was 2.24  ±  1.11( 0.8 – 4.7gm),The mean creatinine was 0.61  ±  0.16  (0.3 – 1.1 mg%) 
median 24 hr urinary protein was 1300 mg. The median time for remission was 212 days. The 
median duration of follow up was 106.8 days. 
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Figure-6: Outcome of children with Diffuse Mesangial Hypercellularity  
  
 
CR – Complete remission ; PR – Partial remission ; SR – Sustained remission; SPR – Sustained partial 
remission ; NR – No remission;   No F/U – No follow up.  
 
Figure 6 shows the treatment out come of diffuse mesangial hypercellularity . Among 53 patients 
of diffuse mesangial hypercellularity 23 ( 43.39% ) achieved complete remission,3 ( 5.66%) 
patients achieved partial remission,1 (1.88%) patient did not achieve remission, 23 ( 43.39% ) 
patients did not come for follow up. Among the complete remission group 9 ( 39.13%) patients 
were treated with only steroid,9 (39.13%)patients were on combination of steroid & 
cyclophosphamide,1 patient was on steroid & mycophenolate,4 patients were on combination of 
steroid & levamisole.  
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Table 10: Characteristics of focal segmental glomerulosclerosis (FSGS). 
Focal Segmental Glomerulosclerosis(FSGS)   (n = 59) Characteristics 
Gender (M:F) 2.2 :1 
Age (Mean ± SD, Range) 11.6 ± 5.4, 1.2 – 18 
Nephrotic: Subnephrotic 44:11(valid 55) 
Time for remission (Median days, range) 167, 15 – 1295 
Follow up in days (Median Range) 562.5. 15 – 2200 
Creatinine (Mean ± SD, Range) 1.28 ± 1.2, 0.3 – 6.8 mg% 
24 Hr Urine protein (Median, Range) 4200, 64mg – 17.0 gm 
Serum albumin (Mean ± SD, Range) 2.1 ± 1.12, 0.67 – 4.3gm 
Hypercholesterolemia 28(77.8%) valid for 36 pt only 
 
Males were predominant in this group (M: F = 2.2:1). The mean age was 11.6 ± 5.4 years (range: 
1.2 – 18). Mean creatinine value was 1.28  ±  1.2 mg% (range:0.3 -6.8),mean serum albumin was 
2.1  ±  1.12,  0.67 – 4.3 gm whereas median 24 hour median urinary protein was  4200 mg 
(mean: 64 mg – 17.0 gm). The median days of follow up was 562 days (range: 15 -2200) and the 
median time for remission was 167 days (range: 15 -1295).  
 
Table 11: Treatment received (prior to coming to CMC vellore) 
Drug Frequency Percent (%) 
No Treatment 9 15.3 
Prednisolone 47 79.7 
Pred nisolone + Cyclophosphamide 1 1.7 
Prednisolone  + Cyclosporine 1 1.7 
ACE Inhibitor 1 1. 7 
Total 59 100.0 
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Figure 7: Outcome of patients with focal segmental glomerulonephritis (FSGS)  
 
 
 
 
 
 
 
 
 
 
 
 
 
             
CR – Complete remission ; PR – Partial remission ; SR – Sustained remission; SPR – Sustained 
partial remission ; NR – No remission;   No F/U – No follow up. 
 
Figure 7 Shows the outcome of patients with focal segmental glomerulonephritis (FSGS). Out of 
59 patients with FSGS, 17(28.81%) patients achieved complete remission, 6(10.16%) patients 
achieved partial remission,3 patients had relapse , 18 (30. 50% ) did not achieve remission, 
15 ( 25.42% ) lost follow up after biopsy.  
Among the complete remission group 13(76.47%) patients were treated with only steroid.  
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1 (5.88%) patient was treated with combination of steroid & cyclosporine, 3(17.64%) patients 
were treated with combination of steroid & cyclophosphamide. 6 ( 10.16%) patients were in 
partial response only treated with steroid. Among the resistant group 14 (77.77%) were treated 
with steroid,1 patient was on combination of steroid & cyclosporine, 2 patients were treated with 
steroid & cyclophosphamide, 1 patient was treated with combination of steroid & 
mycophenolate.   
 
Table 12: Characteristics of patients with IgA nephropathy 
IgA Nephropathy(IgAN) (n =61) Characteristics 
Gender (M:F) 1.4 : 1 
Age (Mean ± SD, Range) 14.6 ± 3.3, 4 – 18 
Nephrotic: Subnephrotic 28:30 (valid 58) 
Time for remission (Median days, range) 147, 71  - 3107 
Follow up in days (Median Range) 567, 86 - 3522 
Creatinine (Mean ± SD, Range) 1.59 ± 0.23, 0.4 – 8.8 mg% 
24 Hr Urine protein (Median, Range) 1200, 17mg – 11.1gm 
Serum albumin (Mean ± SD, Range) 3.3 ± 0.95, 1.2 – 4.9 gm 
Hypercholesterolemia 19 (65.5%) valid for 29 pt only 
 
Table 12 shows the characteristics of 61 patients with IgA nephropathy . Males were 
predominant in this group (M: F = 1.4:1). The mean age was 14.6 ± 3.3 years (range: 4 – 18). 
Mean creatinine value was 1.59 ±  0.23 mg% (range:0.4 -8.8) whereas median 24 hour urinary 
protein was  1200 mg (mean: 17 mg – 11.1 gm). The median days of follow up was 567 days 
(range: 86 -3522) and the median time for remission was 147 days (range: 71 -3107).  
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Table 13: Treatment received (prior to coming to CMC vellore)  
Drug Frequency Percent (%) 
No Treatment 37 60.7 
Prednisolone 21 34.4 
Anti hypertensives 1 1.6 
ACE Inhibitors 1 1.6 
Native medication 1 1.6 
Total 61 100 
 
Table 13 shows total of 61 patients of IgA nephropathy prior to coming to us 21  were treated, 
(34.4%) were treated with prednisolone. One patient each was treated with antihypertensive 
drug, ACE inhibitor and native medications. 37 (60.7%) patients did not receive any treatment.  
Table 14 :  Histologic picture in patients with IgA nephropathy. 
 Frequency Percent 
IgA Nephropathy 41 67.2 
IgA nephropathy + Crescents 7 11.5 
HSP 5 8.2 
End Stage IgA 8 13.1 
Total 61 100 
 
Table 14 shows the characteristic histologic picture by light microscopy in patients with IgA 
nephropathy. Out of a total of 61 cases, features of only IgA nephropathy was seen in 41 (67%) 
of patients; IgA nephropathy with crescents were seen in 7(11.5%) patients whereas end stage 
IgA nephropathy was seen in 8(13%) of cases. 
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Figure – 8: Outcome of patients with IgA nephropathy 
 
            
             
             
             
             
             
             
    
 
 
 
         
          
 
CR – Complete remission ; PR – Partial remission ; SR – Sustained remission; SPR – Sustained 
partial remission ; NR – No remission;   No F/U – No follow up.     
        
Figure 8 shows the outcome of IgA patients. Out of 61 patients with IgA nephropathy,  21 
(34.42%) patients achieved complete remission,12 (19.67%) patients did not achieve 
remission.1(1.6%)  patient had relapse, 4 (6.55%) patient went into end stage renal disease.26 
(42.62%) patient lost follow up. 
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Table 15: Characteristics of patients with Mesangial proliferative glomerulonephritis . 
Mesangio Proliferative GN (n =146) Characteristics 
Gender (M:F) 2.1 : 1 
Age (Mean ± SD, Range) 12.4 ± 4.5, 2- 18 
Nephrotic: Subnephrotic 100:33 (valid for 133 pts) 
Time for remission (Median days, range) 189, 28 – 3302 
Follow up in days (Median Range) 425, 28 – 3302 
Creatinine (Mean ± SD, Range) 0.89 ± 0.79, 0.2 – 6.7 mg% 
24 Hr Urine protein (Median, Range) 1.8gm, 12 mg – 20.0gm 
Serum albumin (Mean ± SD, Range) 2.8 ± 1.16, 0.9 – 4.9gm 
Hypercholesterolemia 63 (43.2%) valid for 84 pt only 
 
Table 15 shows the distribution of Mesangio proliferative glomerulonephritis . The total number 
of patients was 146. Mean age was 12.4 ± 4.5, 2 - 18 years and it showed male preponderance. 
Mean creatinine was 0.89  ±  0.79, 0.2 – 6.7 mg%, mean serum albumin was 2.8  ±  1.16, 0.9 – 
4.9 gm whereas median 24 hour mean urinary protein was 1.8 gm (range :12 mg – 20 gm). The 
median  days of follow up was 425 days (range: 28 -3302) and the median time for remission 
was 189 days (range: 28 -3302) 
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Table 16: Histological types of Mesangial proliferative GN. 
LM Biopsy proven (n = 146) Frequency 
 
Percent 
% 
Mesangial proliferative GN 100 68.5 
Mesangial proliferativ GN + Fibrous crescents 2 1.4 
Mesangial proliferativ GN + Segments of Sclerosis 24 16.4 
Mesangial proliferative GN with glom hyalinization 1 0.7 
Mesangial proliferative GN + Segmental & global 
glomerulosclerosis 
1 0.7 
Diffuse mesangial proliferative GN 3 2.1 
Mesangial Prol. GN with resolving PIGN 14 9.6 
Mesangial proliferaive GN with Interstitial foarm cells  1 0.7 
Total 146 100 
 
Table 16 shows the various histological types of Mesangial proliferative GN. Only mesangial 
proliferative features were seen in the maximum (68.5%) cases whereas Mesangial proliferation  
with segments of sclerosis were seen in 16% cases. Mesangial proliferation  with resolving PIGN 
was seen in about 10% cases. 
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Table 17.  Treatment received (prior to coming to CMC vellore)   
Drug Frequency Percent (%) 
No Treatment 57 39 
Prednisolone 85 58.2 
Pred + Endoxan 3 2.1 
Pred + MMF 1 0.7 
Total 146 100 
 
Figure-9: Out come of patients with Mesangial proliferative GN 
 
 
         
         
         
         
         
         
         
         
         
          
 
CR – Complete remission ; PR – Partial remission ; SR – Sustained remission; SPR – Sustained partial 
remission ; NR – No remission;   No F/U – No follow up.       
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Figure 9 shows out come of  patients  with  Mesangial proliferative GN.  
Among 146 patients 58 ( 39.72%) achieved complete remission ,13 ( 8.90%) patients  achieved 
partial remission, 8 ( 5.47%) patients had relapse, 26 ( 17.80%)  patients did not achieve 
remission.17 ( 11.64%)  patients lost follow up, 24  (16.43% ) patients did not receive any 
treatment. 
Among the complete remission group 37 ( 63.79% ) patient were treated with only steroid. 2  
(3.44%) patients were treated with only levamisole, 2 (3.44%) patients were treated with 
combination of steroid and cyclosporine,14(24.13%) patients were treated with combination of 
steroid & cyclophosphamide, 1(1.72% ) patient was treated with combination of steroid with 
azathioprine,2(3.44%) patients were treated with combination of steroid and levamisole. 
Among 13 patients who had partial remission 12 (92.30%) of them were treated with steroid and 
1( 7.69%)  had received combination of steroid and levamisole. 
Among the 26 patients who did not achieve remission, 17 (65.38% ) patients were treated with 
steroid, 3 (11.53%) were treated with  mycophenolate, 1( 3.84% ) patient was treated with 
levamisole,3 (11.53% ) patients were treated with combination of steroid and cyclosporine, 
1( 3.84% )patient was on combination of steroid and azathioprine,1 (( 3.84% ) patient was 
treated with combination of steroid and mycophenolate.  
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Table: 18  Characteristics of patients with Lupus Nephritis (LN) 
Lupus Nephritis (n=98) Characteristics 
Gender (M:F) 1: 6.4 
Age (Mean ± SD, Range) 15.37 ± 2.5, 8.5 -18 
Nephrotic: Subnephrotic 50:39 (valid: 89/98) 
Time for remission (Median days, range) 209,21 – 3209 
Follow up in days (Median Range) 905, 21 – 3209 
Creatinine (Mean ± SD, Range) 1.5 ± 0.20, 0.4 – 15.6mg% 
24 Hr Urine protein (Median, Range) 0.8gm, 24 mg – 1.6 gm 
Serum albumin (Mean ± SD, Range) 2.7 ± 0.9, 0.4 – 4.6gm 
Hypercholesterolemia 23(23.5%) valid for 29 pt only 
Antinuclear antibody positive 79 (80.6%)  
Comlement level C3 low ( <90 ) 39 pt ( valid for 41  pt ), 95.1% 
Comlement level C4 low ( 10) 25 pt( valid for 41  pt ), 61.0% 
Anti DS DNA antibody  Elevated in 48 pt ( valid upto 68pt ),70.6% 
20 pt ( 29.4%)  DsDNA  Normal.(  < 30) 
 
Table 18 shows the characteristics of 98 patients with LN . Females were predominant in this 
group (M: F = 1:6.4). The mean age was 15.37 ± 2.5, 8.5 - 18 (range: 8.5 – 18). Mean creatinine 
was 1.5  ±  0.20, 0.4 – 15.6 mg%, whereas median 24 hour urinary protein was 0.8 gm (mean: 24 
mg – 1.6 gm),Mean serum albumin 2.7  ± 0.9, 0.4 – 4.6 gm. The median  days of follow up was 
905 days (range: 21 -3209) and the median days for remission was 209 days (range: 21 -2256). 
Table  19.Various classes of  Lupus nephritis. 
WHO classes of LN Frequency Percent (%) 
Class I 1 1.0 
Class II 17 17.3 
Class III 8 8.2 
Class IV 66 67.4 
Class V 6 6.1 
Total 98 100 
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Table  19  shows  based on the initial biopsies  the various histological classes of patients with 
Lupus nephritis were 66 (67.4%) patients had class IV LN and it constituted the largest group. 
Class II was the second  largest group 17(17.3%) cases whereas class III, class V and class I 
constituted 8(8.2%) , 6(6.1%)  and 1 (1.0% respectively. 
 
Table - 20:  Treatment received (prior to coming to CMC vellore) 
Drug Frequency Percent 
No Treatment 13 13.4 
Prednisolone 79 80.4 
Prednisolone + Cyclophosphamide 2 2.1 
Prednisolone + IV Cyclophosphamide 1 1.0 
Azathioprine 1 1.0 
Immunoglobulin 1 1.0 
Prednisolone + Cyclophosphamide + Azathioprine 
+ Cyclosporine 
1 1.0 
Total 98 100 
 
Table 20 :  shows the distribution of patients who had been treated with different drugs before 
presenting to us. Out of 98 cases, 78 (79.6%) patients were treated with prednisolone and this 
constituted the largest group. Two (2%) patients had received prednisolone and 
cyclophosphamide whereas 13 (13%) patients had not received any treatment before presenting 
to us. 
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Figure 10: Outcome of patients with Lupus Nephritis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
CR – Complete remission ; PR – Partial remission ; SR – Sustained remission; SPR – Sustained 
partial remission ; NR – No remission;   No F/U – No follow up.     
      
Figure 10 shows Outcome of 98 patients with Lupus Nephritis. Complete remission was 
achieved in 29 cases (12 – sustained remission, 3 relapses) whereas 1 patient had partial 
remission .24 patients did not achieve remission. 42 patients lost follow up after first revisit. On 
final follow up 5 children approached end stage renal disease. 
The various classes of lupus nephritis were treated with various immunosuppression 
medications. 
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Among the 29 children who went into complete remission, class IV LN  18(62.06%),class III LN 
4 (13.79%),class II LN 4 (13.79%),class V LN 3 (10.34%),non of them were class I . Among the  
18 children  with class IV LN, 2 received only prednisolone,10 received combination of  
prednisolone and Azathioprine,5 received combination of prednisolone and cyclophosphamide,1 
child received combination of prednisolone and mycophenolate. Of the 4 children with  class III 
LN who went into remission 3 children were treated with  combination of prednisolone and 
Azathioprine , 1 child was treated with combination of prednisolone  and mycophenolate. Of the 
4 children with  class II LN who went into remission all were treated with combination of 
prednisolone and Azathioprine. There were 3 children in  class V LN who achieved remission  2 
were treated with  combination of prednisolone and Azathioprine and 1 was treated with 
combination of prednisolone and cyclosporine. 
Table  21: Characteristics of patients with Acute Proliferative 
Glomerulonephritis  
 Proliferative Glomerulonephritis (n=81) Characteristics 
Gender (M:F) 1.6:1 
Age (Mean ± SD, Range) 13.4 ± 3.9, 1 – 18 
Nephrotic: Subnephrotic 46:30 (valid:76/81) 
Time for remission (Median days, range) 152, 16 – 2125 
Follow up in days (Median Range) 252, 16 – 2910 
Creatinine (Mean ± SD, Range) 2.0 ±0.37, 0.4 – 25.0mg% 
24 Hr Urine protein (Median, Range) 2.2gm, 34 mg – 12.7gm 
Serum albumin (Mean ± SD, Range) 2.73 ± 1.03, 0.2 – 4.5gm 
Hypercholesterolemia 224(29.6%) valid for 34 pt only 
 
Table 21 shows the characteristics of 81 patients with Proliferative Glomerulonephritis . Males 
were predominant in this group (M: F = 1.6:1). The mean age was 13.4 ± 3.9 years (range:1- 18). 
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Mean creatinine was 2.0 ± 0.37 mg%, (range:0.4 -25 mg%),mean serum albumin was 2.73  ± 
1.03,(range : 0.2 – 4.5 gm)   whereas median 24 hour mean urinary protein was 2.2 gm (range : 
34 mg – 12.7 gm). The median days of follow up was 252 days (range: 16 -2910) and the median 
days of remission was 152 days (range: 16 -2125).  
Table : 22, Various histological finding in  Proliferative GN 
 Frequency Percent (%) 
Proliferative GN 1 1.2 
Focal proliferative GN 1 1.2 
Focal segmental proliferative GN 8 9.9 
FS proliferative GN with fibrocellular crescents 1 1.2 
Focal proliferative and sclerosing GN 3 3.7 
Acute proliferative GN 4 4.9 
Diffuse proliferative GN 3 3.7 
Diffuse endo capillary exudative proliferative GN 47 58.0 
DPGN + cellular crescents 4 4.9 
DPGN + Fibrocellular crescents 5 6.2 
DPGN + Segmental capillary wall thickening 3 3.7 
End stage proliferative and sclerosing GN 1 1.2 
Total 81 100 
 
Table 22 shows, Diffuse endocapillary and proliferative glomerulonephritis constituted the 
largest group and it was seen in 47 (58%) cases. Focal segmental proliferative GN was seen in 8 
(9.9%) cases.  
Table 23 Treatment received  prior to coming to CMC vellore 
 Frequency Percent 
No Treatment 53 65.4 
Prednisolone. 26 32.1 
Anti hypertensives 2 2.5 
Total 81 100 
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Figure – 11: Outcome of patients with Proliferative Glomerulonephritis. 
 
 
 
 
             
             
             
             
             
  
 
 
 
         
         
         
         
CR – Complete remission ; PR – Partial remission ; SR – Sustained remission; SPR – 
Sustained partial remission ; NR – No remission;   No F/U – No follow up.   
         
Figure 11: shows the status of 81 patients with Proliferative Glomerulonephritis. 27 (33.33%) 
patients achieved complete remission, 3(3.70% ) patients achieved  partial remission,18 
(22.22%) patients did not achieve remission, 1( 1.23%) patient developed end stage renal 
disease. 32 (39.50%) patients lost follow up.  
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Out of 27 patients who were in complete remission 20 (74.04%) were treated  with  only steroid , 
1(3.70%) patient was on combination of steroid  and  cyclosporine, rest 6 (22.22%)were not 
given any treatment.18 patients did not achieve remission, 16(88.88%) of them were treated with 
steroid only.Rest 2 were treated with combination of  steroid and mycophenolate & steroid and 
azathioprine.  
Table - 24 : Characteristics  of   patients  with  Crescentic glomerulonephritis 
Crescentic glomerulonephritis (n=15) Characteristics 
Gender (M:F) 1:4 
Age (Mean ± SD, Range) 14.83 ± 4.09, 4 – 18 
Nephrotic: Subnephrotic 8 (80%) : 2 (20%) valid for 10 patients only 
Time for remission (Median days, range) 206.5 (26 – 762) 
Follow up in days (Median Range) 206.5 (26 – 762) 
Creatinine (Mean ± SD, Range) 5.62 ± 2.85 , 1.2 – 11.6mg% 
24 Hr Urine protein (Median, Range) 4.6gm, 0.749 mg – 8.6gm 
Serum albumin (Mean ± SD, Range) 2.12 ± 0.73, 0.73– 2.7gm 
Hypercholesterolemia 2 (valid for 2 pt only) 
 
Table - 24  shows the characteristics  of 15 (1.69%)  patients  with  Crescentic 
glomerulonephritis 
 Membranous glomerulonephropathy  accounted for  24(2.70%) ,13 out of 24 were in 
remission during the first revisit,10 of them were treated with combination of steroid and 
cyclophosphamide,3 were treated with only steroid. 
Membrano proliferative glomerulonephritis  contributed to  8(0.9 %). 
Electron microscopy  examination  reports were  available  for  14 pts( 1.6%). Among them             
9(1%) Alports syndrome ,  MPGN  was  0.1%,  only  mild foot process effacement  was  seen  in 
3%  and  Inconclusive  reports  in 0.1% case. 
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DISCUSSION 
The underlying histopathological characteristics in nephrotic syndrome are of immense 
significance in determining steroid responsiveness and long-term prognosis.  
Several studies have reported on the relative distributions of various diagnostic categories 
in large series of paediatric renal biopsies. As there may be differences in the protocol or 
indication for biopsy across centers or countries, the results may not be directly comparable, but 
they do provide an overview of the most commonly encountered entities. 
In the study reported by ISKDC14 on renal biopsies done for 521 children, the distribution of 
various histological diagnosis  were as follows: Minimal change nephrotic syndrome 398  
(76.4%), Membranoproliferative glomerulonephritis 39(7.5%), Focal & segmental 
glomerulosclerosis 36(6.9%),  Proliferative glomerulonephritis 12(2.3%), Pure diffuse mesangial 
proliferation 12 (2.3%), Focal & global glomerulosclerosis 9(1.7%), Membranous 
glomerulonephropathy 8(1.5%), Chronic glomerulonephritis 3(0.6%), Unclassified 4 (0.8%). 
In the Italian National Registry of renal biopsies in children, the distributions of the 
most common glomerular diseases were, in order of frequency, IgA nephropathy, Henoch– 
Scho¨nlein nephritis, minimal-change disease (MCD), focal segmental glomerulosclerosis 
(FSGS), mesangial proliferative glomerulonephritis, membranoproliferative glomerulonephritis, 
lupus nephritis and TGBM disease/Alport syndrome. In this series, the indication for renal 
biopsy was isolated microscopic haematuria in 20% of cases, non-nephrotic proteinuria with or 
without microscopic haematuria in 30%, nephrotic-range proteinuria in 35% and acute or chronic 
renal failure in 15%61. 
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The largest single study reported on more than 1700 paediatric renal biopsies from a 
Korean registry, in which the most common primary glomerular conditions were MCD (25%), 
IgA nephropathy (10%), acute post-infectious glomerulonephritis (9%), and FSGS (4%), with 
Henoch–Scho¨nlein and lupus nephritis as the most common secondary conditions62. 
Similarly, the study published from the Czech registry on 709 biopsies in children, 
reported the most common diagnoses in children to be IgA nephropathy (19%), MCD (18%) and 
TGBM nephropathy (12.3%)63. 
In another series of 322 children specifically presenting with haematuria, the frequencies 
of various diseases were IgA nephropathy in 24%, Alport nephropathy in 27%, TGBM  
nephropathy in 16%, other glomerulopathy in 19% and normal glomeruli in the remaining 
15%64. 
In a study from India, in 250 children with pure nephrotic syndrome, Minimal Change 
Disease comprised more than half of the cases65. 
In another report from Great Ormond Street Hospital,  from an unselected series of more 
than 1250 consecutive paediatric renal biopsies for all non-tumour indications has demonstrated 
a range of histological findings out of which  MCD, IgA nephropathy and Henoch–Scho¨nlein 
nephritis represent the most common entities66. 
In two other studies including more than 300 children biopsied for steroid-resistant or 
atypical nephrotic syndrome from India, FSGS was diagnosed in 40%, followed by minimal-
change nephropathy in 20–30%, Membranoproliferative GN in 15%, mesangial proliferative  in 
10% and membranous in 5% children. In younger children, however, MCD was the most 
common entity, whereas FSGS predominated in the older children41, 67. 
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A study  done from India has shown the analysis of  910 renal biopsy  in which the the 
commonest indication for renal biopsy was nephrotic syndrome.The histopathological  diagnoses 
were as follows,diffuse mesangioproliferative glomerulonephritis as commonest 36%, minimal 
change disease 24.75%,focal segmental glomerulosclerosis 11.5%, IgM 1.3%, and IgA 
nephropathy 1.2%,systemic vasculitis 2.5%68. 
A study done from our centre has shown the histopathological reports of all native kidney 
biopsies performed from 1990 – 2001. Total number of biopsies were 5258 out of which 928 
were children (<15 years). The various histological diseases were MCD in 47.2%. 
FSGS in 12.5%, mesangial PGN in 11.3%, endocapillary proliferative GN in 8.8% and lupus 
nephritis in 3.5% children69. The incidence of MPGN had declined to 2.6% in this study when 
compared to 7.2% between 1970 and 1985. 
In the present study, the distribution of various diseases were as follows: Minimal change 
disease in 303 (34.16%), Mesangial proliferative GN in 146 (16.45%), Lupus nephritis in 
98(11.05%), Proliferative glomerulonephritis in 81(9.13%), IgA nephropathy  in 61 (6.87%), 
Focal segmental glomerulosclerosis  in 59(6.65%), Diffuse mesangial hypercellularity in 
53(5.97%), Membranous glomerulonephropathy  in 24(2.70%), Crescentic glomerulonephritis in 
15(1.69%), Membrano proliferative glomerulonephritis  in 8(0.9 %),Hemolytic uremic syndrome 
in 5 (0.56 %),Vasculitis in 3(0.33 %), acute interstitial nephritis in 3(0.33 %), acute tubular 
necrosis  in 2(0.22 %), granulomatous interstitial nephritis in 3(0.33%), end stage etiology of 
unknown etiology in 17(1.92 %) and  inadequate sample in 2 (0.22%) children. It appears that 
the incidence of Lupus nephritis is higher in our patients in comparison to other study published 
in literature69. The same also has been shown in another study 70 done on lupus nephritis in 
paediatric population. 
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In the study published by ISKDC14,  the  number of children with less than or equal to 6 
years of age with a histological diagnosis of MCD, FSGS and MPGN were 79.6%, 50% and 
2.6% respectively. In this study, the respective percentages in MCD and FSGS are 43.9%, 
25.4%. None of the children with MPGN were below 6 yrs of age.  In a study published in 
children with lupus nephritis70, the median age was 13.7 years and female:male ratio was 5.5:1 
and in our  study  patients with lupus nephritis, the median age was 15.3 years and female :male 
ratio was 6.4 : 1. 
Hypertension was seen in 20.7 % patients with MCD, 48.5 % patients with FSGS and 
51.4% patients with MPGN in the study published by ISKDC14. In our patients, hypertension 
was seen in 7% patients with MCD, 21.1%patients with FSGS and 12.1 % patients with MPGN. 
Hypertension was seen in 59% of children with lupus nephritis70. Hypertension was seen in 
19.6% of patients with lupus nephritis in our patients. Hypertension was seen in 15.7% children 
with mesangioproliferative GN and 8.2% of children with IgA nephropathy. 
Similarly, haematuria was seen in 22.7% patients with MCD, 48.4% patients with FSGS 
and 58.8% patients with MPGN in the study published by ISKDC14 . In our patients, haematuria 
was seen in 9% patients with MCD, 12.8% patients with FSGS and 28.6% patients with MPGN. 
Haematuria was seen in 31.7 % children with mesangioproliferative GN, 46.5% of children with 
IgA nephropathy and 13.7% of children with lupus nephritis. 
In the study published by ISKDC71 in 389 children with MCD, 92% children responded 
to steroid and out of them 41% had a sustained remission whereas, 48% of children either had a 
single or multiple relapse. In this study, among the 303 patients with MCD, 70% responded to 
steroid and out of them, 33% had sustained remission on long term follow up. 
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In patients with lupus nephritis, the initial response to steroid either alone or combination 
with other immunosuppressive drugs has been shown to be 87% in a study published from South 
Korea72. However, in this study the response in lupus nephritis has been found to be 53%. 
In patients with FSGS, the complete response to steroid was seen in 38% children and 
steroid resistant was seen in 29% of children in a recent study published from Brazil73. In our 
patients with FSGS, the complete response to steroid was seen in 32% of children whereas 30% 
of children were found to be resistant to steroid. 
 
Conclusion: 
Among the children, who present with nephrotic syndrome, Minimal Change Disease 
(MCD) is found to be the commonest histopathological diagnosis in children under 8 years of 
age. The incidence of MPGN has declined in this study and a similar trend has been shown in 
other studies as well.  The response of children with MCD to corticosteroid is comparable to that 
available in literature. The incidence of lupus nephritis has been found to be increased in this 
study; however the response to steroid is found to be less in comparison to literature. The 
response of children with FSGS to steroid is similar to that published in literature. 
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Picture 1. Minimal Change Disease.   Picture 2  Mesangial  Proliferative GN. 
Arrow points to normal mesangial   Arrow  points to mesangial  proliferation 
cellularity. H &E stain, magnification 40x.  H &E stain, magnification 40x. 
  
 
        
 
 
 
Picture 3  Diffuse  proliferative GN.             Picture 4  Membranous nephropathy 
Arrow  points to diffuse proliferation  of the  Arrow points  uniform  increased   
Mesangial cells &  endocapillary cells.               capillary wall thickening. 
H &E stain, magnification 40x. .    H &E stain, magnification  40x. 
 
 
 
 
 
 
 
 
 
 
    
 
 
Picture-5  Membranoproliferative GN. Picture-6  Advanced Membranous . 
Arrow points to increase lobultion,  nephropathy. Arrow points uniform 
intracapillary  hypercellularity and   thickening of capillary wall. 
thickening  of capillary wall.            H &E stain, magnification 40x. 
H &E stain, magnification 40x. 
 
  
      
 
Picture 7  Crescentic GN.     Picture  8   Vasculitis. Arrow  points 
Arrow  points to circumferential cellular        necrotizing  and crescentic GN. 
crescent . H &E stain, magnification 40x.        H &E stain, magnification 40x. 
 
 
           
             
 
 
 
 
         
 
Picture 9  Focal segmental    Picture  10 End stage histology. 
glomerulosclerosis.     Arrow shows global glomerulosclerosis. 
Arrow shows segmental  sclerosis.   H &E stain, magnification 40x 
H &E stain, magnification 40x 
 
   
   
       
        
       
        
 
 
Picture 11 Acute interstitial nephritis.   Picture 12  Acute tubular necrosis. 
Arrow points to dense mononuclear cell infiltration. Arrow points to injured tubules,loss of  
H &E stain, magnification 10x. tubular epithelial cell height and brush 
burder. H &E stain, magnification  40x. 
     
 
 
 
         
 
Picture 13 Minimal change disease.  Picture 14 MPGN type II Electron dense 
Diffuse effacement of foot processes seen on  deposits within the basement membrane 
 electron microscopy (×800)    electron microscopy (×800) 
 
 
 
 
 
          
  
Picture 15,16 : Alports syndrome . Arrow shows basement membrane showing 
segments of thickening and thinning with irregular contours (left panel). Magnification of a 
thickened segment showing lamellation, electron-lucent areas and electron-dense 
granules (right panel). 
 
 
 PROFORMA 
 
A. Patient Information: 
1. Case Number: 
2. Name:  
3. Hosp_No:      
4. Age:           
5. Gender :  Male - 0   /   Female - 1                            
6. Ht:          Cm               
7. Wt.:        Kg.    
8. State Code:            
B. Clinical Features: 
9. Edema:  No- 0  / Limited-1  / Generalised - 2 
10. HTN:    No - 0   /  Yes - 1 
11. Hematuria: No - 0  / Microscopic - 1  /  Macroscopic - 2 
12. Oliguria :   No - 0  / Oliguria - 1  / anemia - 2   
13. Skin Rash: No - 0  / Yes - 1              
14. Eye abn:  No - 0  / Yes - 1           
15. Hearing : No - 0 / Yes - 1                  
16. Pallor :  No - 0   / Yes - 1 
17. Arthritis: No - 0 / Yes - 1                   
18. Others if any:    
19. Duration of Illness ( in Weeks) : 
 
C. Lab Investigations : 
20. HB:           
21. Urea:    
22. Creatinine: 
23. S.Alb: 
24. 24hr U/P : 
25. U/P.Ct.Ratio:  
26. Ur.Alb:            
27. Ur.RBC:  
 28. Ur.WBC:    
29. S.Cholestrol:  
30. ANA:     
31. DSDNA: 
32. Total Comple:      
33. C3 :   
34. C4:  
35. ANCA-C: 
36. ANCA-P:   
37. ASO:   
38. ADNB:    
39. RA: 
40. HbsAg:   
41. HCV Ab:    
42. HIV:  
43. Croglobulin: 
 
  D. Clinical Syndrome:  
 
 Acute Nephritic Syndrome - 1    
            Nephrotic Syndrome - 2      
            ARF - 3       
            RPRF - 4 
            Sev.RF unknown etiology - 5     
            Asymtomatic hematuria - 6  
            Subnephrotic protein nos - 7 
 Others - 8. 
 
E. Biopsy Details: 
 
   45. Biop_Date:    
   46. Bx_No:                         
   47. Bx.LM:  
   48. Tot_No of glom:                      
    49. Tot_No of scle:               
   50. No of glom Crescent: 
   51. Tubulo.Interstitial / Infiltration: No - 0 /  Mild - 1 / Moderate - 2 / Severe - 3 
   52. Interstitial fibrosis : No- 0 / Focal - 1 /  Diffuse – 2 
IF:     
IgG : No - 0  / 1+ / 2+ / 3 
IgA : No - 0  / 1+ / 2+ / 3+         
IgM: No - 0  / 1+ / 2+ / 3+  
C3 :   No - 0  / 1+ / 2+ / 3+           
C4:  No - 0  / 1+ / 2+ / 3+    
Pattern:   
Course Granulor  - 1   
Linear contiguous - 2    
Arborising - 3         
Non specific - 4   
Location:  
Mesangium - 1 
Capillay Wall - 2     
Sclerotic tufts - 3 
Complications:  
No - 0   
Bleeding - 1   
Infections - 2 
EM :   
Treatment: 
Rx. given :  No - 0   / Yes - 1 
What Rx  :  Sterioid - No - 0  / Yes - 1       
Endoxen : No - 0  / Yes - 1 / Oral / IV 
CSA :  No - 0  / Yes - 1          
Tacro: No - 0  / Yes - 1     
Aza: No - 0  / Yes - 1   
ACEi: No - 0  / Yes - 1   
ARB: No - 0  / Yes - 1     
Keto: No - 0  / Yes - 1   
Levamisole: No - 0  / Yes - 1   
MPA :No - 0 / MMF - 1 / MM Na - 2 
Follow - Up:   No - 0   / Yes - 1
 Lab Investigations: 
 
Investigations Visit 1 Visit2 Visit3 Visit4  
Date of visit      
Symptoms      
Height      
Weight      
S.Creatinine      
S.Urea      
S.Alb      
24hr U/P      
U/P creat ratio      
HB      
S.Chol        
Remission      
Change of Rx      
Drugs with 
levels 
     
Change of 
protocol 
     
Duration of Rx      
Symptoms: 
Worse - 0    
Same - 1         
Improvement - 2  
No Sym. - 4 
     
Last Visit Date      
 
Note.:For Drugs  if CSA - CO, C2  /  Tac-CO   / MPA  - AUC 
